Synaptic activity: An emerging player in schizophrenia

Brain Research

Volumn 1656, Issue , 2017, Pages 68-75

  Sarkar, Anindita ^a   Marchetto, Maria C ^a   Gage, Fred H ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN PROTEIN; SYNAPTIC PROTEIN; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

DISEASE MODEL; GENE; GLUTAMATERGIC SYNAPSE; HUMAN; IN VITRO STUDY; NERVE CELL; NERVE CELL PLASTICITY; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYNAPSE; ANIMAL; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; HUMANS; SCHIZOPHRENIA; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84951958202     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2015.12.028     Document Type: Review

References (89)

1. Akbarian, S., et al. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res. Rev. 52 (2006), 293–304.
2. Ayalew, M., et al. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol. Psychiatry 17 (2012), 887–905.
3. Bauer, M., et al. Is dopamine neurotransmission altered in prodromal schizophrenia? A review of the evidence. Curr. Pharm. Des. 18 (2012), 1568–1579.
4. Bernstein, H.G., et al. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert. Rev. Neurother. 9 (2009), 1059–1071.
5. Blackwood, D.H., et al. Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am. J. Hum. Genet. 69 (2001), 428–433.
6. Bradshaw, N.J., et al. DISC1-binding proteins in neural development, signalling and schizophrenia. Neuropharmacology 62 (2012), 1230–1241.
7. Brennand, K., et al. Phenotypic differences in hiPSC NPCs derived from patients with schizophrenia. Mol. Psychiatry 20 (2014), 361–368.
8. Brennand, K.J., et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 473 (2011), 221–225I.
9. Brown, A.S., et al. Nonaffective psychosis after prenatal exposure to rubella. Am. J. Psychiatry 157 (2000), 438–443.
10. Brown, A.S., et al. Maternal exposure to respiratory infections and adult schizophrenia spectrum disorders: a prospective birth cohort study. Schizophr. Bull. 26 (2000), 287–295.
11. Cardno, A.G., et al. Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am. J. Med. Genet. 97 (2000), 12–17.
12. Carter, C.J., Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr. Res. 86 (2006), 1–14.
13. Chen, J.F., Adenosine receptor control of cognition in normal and disease. Int. Rev. Neurobiol. 119 (2014), 257–307.
14. Chubb, J.E., et al. The DISC locus in psychiatric illness. Mol. Psychiatry 13 (2008), 36–64.
15. Church, J.A., et al. Control networks in paediatric Tourette syndrome show immature and anomalous patterns of functional connectivity. Brain 132 (2009), 225–238.
16. Clarke, M.C., et al. The role of obstetric events in schizophrenia. Schizophr. Bull. 32 (2006), 3–8.
17. Craddock, N., et al. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr. Bull. 32 (2006), 9–16.
18. Cross-Disorder Group of the Psychiatric Genomics, C., et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 45 (2013), 984–994.
19. Espuny-Camacho, I., et al. Pyramidal neurons derived from human pluripotent stem cells integrate efficiently into mouse brain circuits in vivo. Neuron 77 (2013), 440–456.
20. Fanous, A.H., et al. Genome-wide association study of clinical dimensions of schizophrenia: polygenic effect on disorganized symptoms. Am. J. Psychiatry 169 (2012), 1309–1317.
21. Fernandez, E., et al. The FMRP regulon: from targets to disease convergence. Front. Neurosci., 7, 2013, 191.
22. 2+ channel-regulated neuronal gene expression. J. Neurobiol. 37 (1998), 171–189.
23. Fromer, M., et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 506 (2014), 179–184.
24. Gershon, E.S., et al. After GWAS: searching for genetic risk for schizophrenia and bipolar disorder. Am. J. Psychiatry 168 (2011), 253–256.
25. Gulsuner, S., et al. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell 154 (2013), 518–529.
26. Hahn, C.G., et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat. Med. 12 (2006), 824–828.
27. Hai, A., et al. In-cell recordings by extracellular microelectrodes. Nat. Methods 7 (2010), 200–202.
28. Hai, A., et al. Long-term, multisite, parallel, in-cell recording and stimulation by an array of extracellular microelectrodes. J. Neurophysiol. 104 (2010), 559–568.
29. Hayashi-Takagi, A., et al. Disturbed synaptic connectivity in schizophrenia: convergence of genetic risk factors during neurodevelopment. Brain Res. Bull. 83 (2010), 140–146.
30. Hook, V., et al. Human iPSC neurons display activity-dependent neurotransmitter secretion: aberrant catecholamine levels in schizophrenia neurons. Stem Cell Rep. 3 (2014), 531–538.
31. Horvath, S., et al. Schizophrenia as a disorder of molecular pathways. Biol. Psychiatry 77 (2015), 22–28.
32. Howes, O.D., et al. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 35 (2009), 549–562.
33. Huang, F., et al. Actin polymerization and ERK phosphorylation are required for Arc/Arg3.1 mRNA targeting to activated synaptic sites on dendrites. J. Neurosci. 27 (2007), 9054–9067.
34. Ichikawa, T., et al. Schizophrenia: maternal inheritance and heteroplasmy of mtDNA mutations. Mol. Genet. Metab. 105 (2012), 103–109.
35. Kantrowitz, J.T., et al. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?. Brain Res. Bull. 83 (2010), 108–121.
36. Kirov, G., et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol. Psychiatry 17 (2012), 142–153.
37. Kirov, G., et al. Neurexin 1 (NRXN1) deletions in schizophrenia. Schizophr. Bull. 35 (2009), 851–854.
38. Kolomeets, N.S., The pathology of the hippocampus in schizophrenia. Zh Nevrol. Psikhiatr. Im. S. S. Korsakova 107 (2007), 103–114.
39. Kolomeets, N.S., et al. Decreased numerical density of CA3 hippocampal mossy fiber synapses in schizophrenia. Synapse 61 (2007), 615–621.
40. Kolomeets, N.S., et al. [Pathology of oligodendroglia and myelinated fibers of the hippocampus in schizophrenia (an ultrastructural and morphometric study)]. Zh Nevrol. Psikhiatr. Im. S. S. Korsakova 108 (2008), 52–60.
41. Levinson, D.F., et al. Genome-wide association study of multiplex schizophrenia pedigrees. Am. J. Psychiatry 169 (2012), 963–973.
42. Lewis, D.A., et al. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch. Neurol. 63 (2006), 1372–1376.
43. Lichtenstein, P., et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373 (2009), 234–239.
44. Lieberman, J.A., et al. The American Psychiatric Publishing textbook of schizophrenia. 2006, American Psychiatric Pub., Washington, DC.
45. Majumdar, D., et al. Co-culture of neurons and glia in a novel microfluidic platform. J. Neurosci. Methods 196 (2011), 38–44.
46. Malhotra, D., et al. High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron 72 (2011), 951–963.
47. Malhotra, D., et al. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell 148 (2012), 1223–1241.
48. Meador-Woodruff, J.H., et al. Abnormal kainate receptor expression in prefrontal cortex in schizophrenia. Neuropsychopharmacology 24 (2001), 545–552.
49. Meador-Woodruff, J.H., et al. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res. Bull. 55 (2001), 631–640.
50. Menniti, F.S., et al. Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr. Top. Med. Chem. 13 (2013), 26–54.
51. Millar, J.K., et al. Genomic structure and localisation within a linkage hotspot of Disrupted In Schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia. Mol. Psychiatry 6 (2001), 173–178.
52. 2+ channels in NMDA receptor-independent synaptic plasticity and spatial memory. J. Neurosci. 25 (2005), 9883–9892.
53. Moreno-De-Luca, D., et al. Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. Am. J. Hum. Genet. 87 (2010), 618–630.
54. Mudge, J., et al. Genomic convergence analysis of schizophrenia: mRNA sequencing reveals altered synaptic vesicular transport in post-mortem cerebellum. PloS One, 3, 2008, e3625I.
55. Napoli, I., et al. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E BP. Cell 134 (2008), 1042–1054.
56. Need, A.C., et al. Schizophrenia genetics comes of age. Neuron 83 (2014), 760–763.
57. Network, et al. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat. Neurosci. 18 (2015), 199–209I.
58. Nicholas, C.R., et al. Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. Cell Stem Cell 12 (2013), 573–586.
59. Ohi, K., et al. Glutamate Networks Implicate Cognitive Impairments in Schizophrenia: Genome-Wide Association Studies of 52 Cognitive Phenotypes. Schizophr. Bull. 41 (2014), 909–918.
60. Osakada, F., et al. New rabies virus variants for monitoring and manipulating activity and gene expression in defined neural circuits. Neuron 71 (2011), 617–631.
61. Perry, T.L., et al. Gamma-aminobutyric-acid deficiency in brain of schizophrenic patients. Lancet 1 (1979), 237–239.
62. Phillips, W.A., et al. Convergence of biological and psychological perspectives on cognitive coordination in schizophrenia. Behav. Brain Sci. 26 (2003), 65–82 discussion 82-137I.
63. Plath, N., et al. Arc/Arg3.1 is essential for the consolidation of synaptic plasticity and memories. Neuron 52 (2006), 437–444.
64. Pocklington, A.J., et al. Novel Findings from CNVs Implicate Inhibitory and Excitatory Signaling Complexes in Schizophrenia. Neuron 86 (2015), 1203–1214.
65. Purcell, S.M., et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 506 (2014), 185–190.
66. Rees, E., et al. Analysis of copy number variations at 15 schizophrenia-associated loci. Br. J. Psychiatry 204 (2014), 108–114.
67. Ripke, S., et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. Genet. 45 (2013), 1150–1159.
68. Robicsek, O., et al. Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients. Mol. Psychiatry 18 (2013), 1067–1076.
69. Roussos, P., et al. A role for noncoding variation in schizophrenia. Cell Rep. 9 (2014), 1417–1429.
70. Schizophrenia Working Group of the Psychiatric Genomics, C., Biological insights from 108 schizophrenia-associated genetic loci. Nature 511 (2014), 421–427.
71. Seeley, W.W., et al. Neurodegenerative diseases target large-scale human brain networks. Neuron 62 (2009), 42–52.
72. Shepherd, J.D., et al. New views of arc, a master regulator of synaptic plasticity. Nat. Neurosci. 14 (2011), 279–284.
73. Small, S.A., et al. A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat. Rev. Neurosci. 12 (2011), 585–601.
74. Spira, M.E., et al. Multi-electrode array technologies for neuroscience and cardiology. Nat. Nanotechnol. 8 (2013), 83–94.
75. Steward, O., et al. Synaptic activation causes the mRNA for the IEG Arc to localize selectively near activated postsynaptic sites on dendrites. Neuron 21 (1998), 741–751.
76. Steward, O., et al. Selective targeting of newly synthesized Arc mRNA to active synapses requires NMDA receptor activation. Neuron 30 (2001), 227–240.
77. Sullivan, P.F., et al. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 60 (2003), 1187–1192.
78. Tanner, C.M., et al. Parkinson disease in twins: an etiologic study. JAMAJ. Am. Med. Assoc. 281 (1999), 341–346.
79. Ting, J.T., et al. Functional consequences of mutations in postsynaptic scaffolding proteins and relevance to psychiatric disorders. Annu. Rev. Neurosci. 35 (2012), 49–71.
80. Torrey, E.F., et al. The viral hypothesis of schizophrenia. Schizophr. Bull. 2 (1976), 136–146.
81. Tsuang, M., Schizophrenia: genes and environment. Biol. Psychiatry 47 (2000), 210–220.
82. Ugolini, G., Advances in viral transneuronal tracing. J. Neurosci. Methods 194 (2010), 2–20.
83. Verge, B., et al. Mitochondrial DNA (mtDNA) and schizophrenia. Eur. Psychiatry 26 (2011), 45–56.
84. Wang, Y., et al. Do shared mechanisms underlying cell cycle regulation and synaptic plasticity underlie the reduced incidence of cancer in schizophrenia?. Schizophr. Res. 130 (2011), 282–284.
85. Wen, Z., et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature 515 (2014), 414–418.
86. Wickersham, I.R., et al. Retrograde neuronal tracing with a deletion-mutant rabies virus. Nat. Methods 4 (2007), 47–49.
87. Woodard, C.M., et al. iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson׳s disease. Cell Rep. 9 (2014), 1173–1182.
88. Yoon, K.J., et al. Modeling a genetic risk for schizophrenia in iPSCs and mice reveals neural stem cell deficits associated with adherens junctions and polarity. Cell Stem Cell 15 (2014), 79–91.
89. Yu, D.X., et al. Modeling hippocampal neurogenesis using human pluripotent stem cells. Stem Cell Rep. 2 (2014), 295–310.